Inflammaging: How Chronic Inflammation Drives Every Major Age-Related Disease

Inflammaging: How Chronic Inflammation Drives Every Major Age-Related Disease

In 2000, Italian immunologist Claudio Franceschi published a paper that reframed how geroscience thinks about aging. Drawing on decades of immune senescence research, he proposed that aging is not primarily a failure of cell maintenance or DNA repair — it is an inflammatory catastrophe that unfolds over decades, driven by three converging sources: the accumulated burden of infections cleared but incompletely resolved over a lifetime, the proliferation of senescent cells secreting a chronic inflammatory cocktail, and the progressive failure of anti-inflammatory resolution mechanisms that normally terminate acute inflammatory responses.

He called it “inflammaging” — and the two decades of research since have validated his framework far beyond what he originally proposed. Inflammaging is now understood as the mechanistic common pathway through which most of the major age-related diseases develop: cardiovascular disease, Alzheimer’s, type 2 diabetes, cancer, sarcopenia, osteoporosis, and macular degeneration all show the same upstream inflammatory signature. Conversely, centenarians — people who reach 100 in good health — consistently show the lowest levels of IL-6, TNF-α, and hsCRP of any age group studied, suggesting that the ability to suppress inflammaging is a primary determinant of exceptional longevity.

As a podiatrist and functional medicine practitioner, I see inflammaging from a unique vantage point. The foot and ankle are simultaneously one of the body’s highest-load mechanical systems and one of its most sensitive early-warning indicators of systemic inflammatory status. Plantar fasciitis that won’t heal, Achilles tendinopathy that doesn’t respond to standard treatment, neuropathic pain that worsens despite optimal glycemic control, chronic wounds that fail to progress through healing phases — all of these, in my clinical experience, correlate with elevated systemic inflammaging markers, and all of them respond better when the systemic inflammatory load is addressed alongside the local mechanical intervention.

Franceschi’s Three-Source Inflammaging Model

Franceschi’s original framework identified three distinct sources of the chronic inflammatory input that accumulates with age. Understanding all three is clinically important because each responds to different interventions.

Source 1: Lifelong Antigen Stimulation (Chronic Infections and Immunosenescence)

Every infection, vaccination, autoimmune flare, and allergic response throughout a lifetime stimulates immune activation and leaves behind memory cells. Over decades, the immune system’s working capacity — its naive T-cell reserve — becomes increasingly occupied by these memory responses, particularly by cytomegalovirus (CMV), which infects 60–80% of adults and never fully clears. CMV reactivation is a major driver of CD28-null T cells (highly pro-inflammatory, poorly regulated), and elevated anti-CMV antibody titers in older adults predict cardiovascular events, cognitive decline, and all-cause mortality independently of traditional risk factors.

This immunosenescence — the gradual remodeling of the immune repertoire toward inflammatory, poorly regulated responses — produces a state of chronic immune activation that persists even in the absence of active infection. The body is perpetually in a low-grade “danger response” mode, with NF-κB activation and cytokine production running at a smolder that never fully extinguishes.

Source 2: Senescent Cell Accumulation and the SASP

Cellular senescence — the state in which a damaged cell permanently exits the cell cycle but refuses to die — is an evolutionarily conserved damage-limitation mechanism. In young organisms, senescent cells are rapidly cleared by NK cells and macrophages. With age, both the rate of senescent cell production (from DNA damage, telomere erosion, oxidative stress) and the failure of senescent cell clearance increase simultaneously, leading to accumulation. As described in the senolytic therapy article in this series, the SASP secretome — IL-1α, IL-6, IL-8, TNF-α, MMP-3, MMP-9, PAI-1 — acts as a continuous local and systemic inflammatory broadcast, driving tissue dysfunction in neighboring cells and measurably elevating systemic cytokine levels.

Source 3: Failure of Inflammatory Resolution

A critical insight from Franceschi’s model — and one that was not fully appreciated until Charles Serhan’s work on specialized pro-resolving mediators (SPMs) in the 2000s — is that inflammaging is not simply too much inflammation. It is the failure of inflammation to resolve. Normal acute inflammation proceeds in two phases: initiation (prostaglandins, leukotrienes, cytokines drive immune cell recruitment) and resolution (lipoxins, resolvins, protectins, and maresins — all derived from omega-3 and omega-6 fatty acids — actively terminate the inflammatory response, clear debris, and restore tissue homeostasis). With aging, SPM synthesis declines significantly: a 2018 study in FASEB Journal found that elderly adults had 40–60% lower plasma resolvin E1 and protectin D1 levels compared to young adults, even in the absence of active inflammatory disease.

This means that in older individuals, even minor inflammatory triggers — a skin abrasion, a subclinical respiratory virus, a night of disrupted sleep — initiate an inflammatory response that runs longer, louder, and with more collateral tissue damage than the same trigger would produce in a 30-year-old. The default assumption that “inflammation is bad” misses the deeper problem: it is unresolved inflammation that kills, not inflammation per se.

NF-κB: The Master Inflammaging Switch and How Aging Permanently Activates It

Nuclear factor kappa B (NF-κB) is the transcription factor at the center of the inflammaging story. Under normal conditions, NF-κB is held inactive in the cytoplasm by its inhibitor IκB. When a pathogen-associated molecular pattern (PAMP) or damage-associated molecular pattern (DAMP) activates a Toll-like receptor, IκB is phosphorylated and degraded, NF-κB translocates to the nucleus, and it drives transcription of over 150 inflammatory genes — including TNF-α, IL-1β, IL-6, IL-8, COX-2, iNOS, and numerous chemokines. This is the canonical inflammatory response.

With aging, NF-κB becomes constitutively activated by a cascade of DAMPs that accumulate in aged tissue: mitochondrial DNA fragments (from dysfunctional mitochondria that leak their contents), oxidized LDL, advanced glycation end-products (AGEs), and the cell-free chromatin fragments released by senescent cells as part of their SASP. A landmark 2007 paper in Genes and Development by David Bhansali and colleagues showed that NF-κB activation in aged skin and brain tissue was 2–4 times higher than in matched young tissue even in the complete absence of infection — and that pharmacological NF-κB suppression in aged mice partially reversed transcriptional aging signatures in multiple tissues.

AGEs: How Dietary and Metabolic Sugar-Protein Complexes Drive NF-κB

Advanced glycation end-products (AGEs) — formed when sugars react non-enzymatically with proteins and lipids — are a major endogenous NF-κB activator that accumulates with both aging and glycemic dysregulation. AGEs bind to RAGE (receptor for advanced glycation end-products), which directly activates NF-κB and generates reactive oxygen species via NADPH oxidase. In diabetic patients, AGE accumulation is accelerated 3–5 times faster than in normoglycemic individuals at the same chronological age, explaining why diabetic complications represent a form of accelerated inflammaging rather than merely “high blood sugar damage.”

The foot and ankle relevance is direct: AGE accumulation in connective tissue reduces collagen cross-link flexibility, stiffening tendons, ligaments, and plantar fascia at a rate proportional to cumulative glycemic exposure rather than to calendar age. Limited ankle dorsiflexion in diabetic patients — a major contributor to forefoot ulceration risk — is driven substantially by AGE-stiffened Achilles tendon collagen. In my practice, HbA1c and estimated AGE load (measured by skin autofluorescence or dietary AGE tracking) are part of every chronic tendinopathy workup in diabetic patients.

The Gut-Inflammation Axis: Leaky Gut, LPS Endotoxemia, and Systemic Inflammaging

One of the most significant advances in inflammaging research over the past 15 years has been the recognition that the gut microbiome is a major regulator of systemic inflammatory tone — and that age-associated changes in gut barrier integrity and microbial composition generate a constant inflammatory signal that contributes substantially to inflammaging burden.

Metabolic Endotoxemia: Low-Grade LPS Translocation

Lipopolysaccharide (LPS) is a structural component of gram-negative bacterial cell walls. Under normal conditions, LPS remains confined within the gut lumen, prevented from systemic entry by the intestinal epithelial tight junction barrier and the mucus layer above it. When this barrier is compromised — through dysbiosis, high dietary saturated fat, alcohol, sleep deprivation, psychological stress, or aging itself — LPS translocates into portal and systemic circulation at low concentrations sufficient to activate TLR4 on macrophages, endothelial cells, and adipocytes.

Patrice Cani and colleagues at UCLouvain coined the term “metabolic endotoxemia” to describe this state and demonstrated in a landmark 2007 Diabetes paper that feeding mice a 4-week high-fat diet elevated plasma LPS by 2–3 fold — producing insulin resistance, hepatic steatosis, and adipose tissue inflammation identical to what would be expected from a 4-week low-dose LPS infusion. In 2017, the same group showed that elevated plasma LPS in humans predicted incident type 2 diabetes with an odds ratio of 1.94 over 9 years, independent of BMI and dietary pattern.

The inflammaging connection: plasma LPS concentrations are 25–40% higher in healthy older adults compared to healthy young adults, even when controlling for BMI, diet, and metabolic status. This age-associated metabolic endotoxemia correlates with IL-6, hsCRP, and insulin resistance, and declines with fiber supplementation, probiotics, and intermittent fasting — interventions that restore tight junction integrity and shift microbial composition toward LPS-producing gram-negative species.

Gut Microbiome Aging: Dysbiosis as an Inflammaging Amplifier

Centenarian gut microbiome studies provide striking evidence for the gut-longevity connection. A 2021 study in Nature Metabolism by Biagi et al. examined gut microbiome composition in individuals aged 22–105. While general gut diversity declined with age in the cohort as a whole, the centenarians and semi-supercentenarians showed a distinct microbiome signature: higher Akkermansia muciniphila (a mucus-layer protective species that reduces LPS translocation), higher Bifidobacterium, and higher short-chain fatty acid (SCFA) production from Firmicutes species. SCFA — particularly butyrate — are the primary energy source for colonocytes and also suppress NF-κB directly through histone deacetylase inhibition, providing a direct mechanistic link between high-fiber diet, centenarian microbiome, and low systemic inflammaging.

Visceral Adipose Tissue: The Inflammaging Endocrine Organ

Visceral adipose tissue (VAT) — the fat deposited in and around the abdominal organs, distinct from subcutaneous fat — is not metabolically inert. It is an active endocrine and immune organ that produces a repertoire of adipokines (adiponectin, leptin, resistin, visfatin) and cytokines (IL-6, TNF-α, MCP-1) at volumes that make it one of the largest sources of systemic inflammatory signal in metabolically obese individuals.

Adipose Tissue Macrophages and the Crown-of-Thorns Lesion

As adipocytes hypertrophy with fat accumulation, they begin to die, and crown-like structures (CLS) — aggregates of macrophages surrounding dead or dying adipocytes — form in visceral fat. These CLS lesions produce continuous local IL-6, TNF-α, and IL-1β at concentrations that, in a large VAT mass, translate to measurable systemic cytokine elevation. A 2018 study in Journal of Clinical Investigation found that VAT macrophage density (CLS count per unit area) correlated more strongly with plasma IL-6 (r=0.71) than did BMI (r=0.43) or total fat mass (r=0.51), suggesting that macrophage activation state in VAT is a more direct driver of systemic inflammaging than simply how much fat a person carries.

The practical implication: waist-to-height ratio (WHtR above 0.5) is a better clinical proxy for VAT inflammaging burden than BMI, because it tracks central adiposity rather than total adiposity. Two people with identical BMI of 28 — one pear-shaped and one apple-shaped — have dramatically different systemic inflammatory loads. I measure WHtR in every functional medicine patient at every visit.

Adipose-Derived Senescent Cells: The Intersection of VAT and SASP

Visceral adipose tissue also accumulates senescent cells at higher rates than most other tissues, particularly in the context of obesity and metabolic syndrome. A 2018 Nature Medicine study by Xu and Baker (from the same group that pioneered the INK-ATTAC mouse model) showed that transplanting adipose tissue from old mice into young mice produced premature physical dysfunction and shortened lifespan — and that the pathological effect was attenuated by first clearing senescent cells from the transplanted tissue with ABT-263. This experiment established that senescent adipose tissue is sufficient, not merely associated, to drive systemic aging — placing VAT senescent cell clearance at the intersection of the senolytic and anti-inflammaging therapeutic strategies.

The Anti-Inflammaging Protocol: Evidence-Based Interventions

The inflammaging literature now supports a multi-target intervention approach, with each strategy addressing one or more of the three source pathways identified by Franceschi. The most effective protocols combine at least three or four of the following simultaneously.

Omega-3 Optimization: SPM Precursor Loading

EPA and DHA are the precursor fatty acids for the resolvin, protectin, and maresin families of SPMs. In clinical trials, supplementation with 2–4 grams per day of EPA+DHA reduces hsCRP by 20–30% and IL-6 by 15–25% in individuals with baseline inflammation, with effects appearing at 8 weeks and maximizing at 6 months. The omega-3 index (target: above 8% of red blood cell fatty acids) is the most direct measure of tissue EPA+DHA status and SPM synthetic capacity. I test omega-3 index in all functional medicine patients and dose EPA+DHA to achieve the target — typically 2–3 grams per day in most individuals eating a standard American diet.

Polyphenols: NF-κB Inhibition via Multiple Pathways

Curcumin (from turmeric), resveratrol (from grape skin and Japanese knotweed), quercetin (from onions, capers, and apples), and EGCG (from green tea) all inhibit NF-κB through partially overlapping mechanisms — blocking IKK phosphorylation, inhibiting p65 nuclear translocation, and activating the anti-inflammatory transcription factor Nrf2. Curcumin at 500–1,000 mg per day with piperine reduces hsCRP by 30–40% in RCTs with elevated baseline inflammation; EGCG at 400 mg per day reduces TNF-α by 22% in overweight individuals in 12-week trials. The bioavailability challenge with all polyphenols is real: standard curcumin supplements have poor absorption, requiring either phospholipid-complexed (Meriva) or liposomal formulations to achieve clinical plasma concentrations.

Mediterranean-Pattern Diet: Anti-Inflammaging Across All Three Sources

The PREDIMED trial’s anti-inflammatory findings deserve specific attention in the inflammaging context. At 5 years, participants randomized to Mediterranean diet with extra-virgin olive oil (EVOO) — which is rich in oleocanthal, a natural COX inhibitor, and oleic acid — showed 30% lower plasma IL-6 and hsCRP compared to the low-fat control arm, alongside the cardiovascular event reduction. The mechanism is multi-target: EVOO reduces LPS-driven TLR4 activation (oleocanthal), fish provides EPA/DHA for SPM synthesis, legumes and fiber feed SCFA-producing gut microbes, and the polyphenol density of vegetables and olive oil directly suppresses NF-κB. No single drug matches this simultaneous anti-inflammaging effect profile.

Exercise: The Most Consistent Anti-Inflammaging Intervention

Exercise produces an acute inflammatory spike (IL-6 from contracting muscle, which acts as a myokine signaling molecule — not a pathological signal) followed by a sustained anti-inflammatory rebound: IL-10 and IL-1ra increase, resting TNF-α and hsCRP fall over weeks to months of regular training. A 2019 meta-analysis in Brain, Behavior, and Immunity of 35 RCTs found that aerobic exercise at moderate intensity 3–5 times weekly reduced hsCRP by 0.31 mg/L on average — clinically meaningful given that a 1 mg/L increase in hsCRP is associated with a 58% higher cardiovascular event risk per the JUPITER trial. The myokine irisin, released from exercising skeletal muscle (as detailed in the strength training article), directly suppresses NF-κB in adipose and hepatic tissue, providing a muscle-to-visceral-fat anti-inflammatory communication pathway that partially explains why exercise preferentially reduces visceral adiposity relative to caloric restriction alone.

Sleep Normalization: The Most Underappreciated Anti-Inflammaging Lever

Sleep deprivation (less than 6 hours per night) elevates IL-6 and TNF-α measurably within 48 hours, and chronically short or poor-quality sleep produces an inflammaging biomarker profile indistinguishable from that of someone 10 biological years older. A 2019 study in Sleep found that adults who normalized their sleep from 5 to 7–8 hours per night with a 12-week CBT-I (cognitive behavioral therapy for insomnia) program showed a 24% reduction in hsCRP and a 19% reduction in IL-6 — greater anti-inflammatory effect than any single dietary supplement in head-to-head comparison trials. Sleep is not passive recovery; it is the primary anti-inflammaging maintenance window in which NF-κB activity falls to its nadir, tissue repair occurs, and the glymphatic system clears inflammatory debris from the brain.

Measuring Your Inflammaging Load: What to Test, What to Target

Unlike many aging biomarkers that require specialized testing, the core inflammaging panel uses standard clinical laboratory tests available through any physician. Here are the markers I use in my functional medicine practice, along with the targets I aim for in patients who are actively pursuing longevity optimization.

hsCRP: The Most Clinically Available Marker

High-sensitivity C-reactive protein (hsCRP) is produced by the liver in response to IL-6. It is the most widely studied inflammaging biomarker and the most clinically accessible. The AHA/CDC define cardiovascular risk tiers as: low (<1.0 mg/L), average (1.0–3.0 mg/L), and high (>3.0 mg/L). For longevity optimization, I target <0.5 mg/L — a level that in longitudinal studies predicts the lowest all-cause mortality across virtually all age cohorts. Note: hsCRP can spike 100-fold during any acute infection or injury; always interpret in the context of recent illness history.

IL-6: The Most Direct Inflammaging Signal

IL-6 is more directly informative than hsCRP because it is upstream in the inflammaging pathway — produced by senescent cells, VAT macrophages, and activated immune cells, then driving CRP production in the liver. Serum IL-6 above 2.0 pg/mL in an older adult without active infection is a red flag for significant inflammaging burden. Centenarians consistently show IL-6 below 1.5 pg/mL despite their age. In my clinical panel, IL-6 declines most rapidly with omega-3 supplementation and sleep improvement — typically by 20–30% within 8–12 weeks of aggressive intervention.

Fibrinogen and TNF-α: Completing the Picture

Fibrinogen — an acute phase protein that directly contributes to thrombotic risk — is elevated by the same inflammatory drivers as CRP and serves as an independent cardiovascular predictor. TNF-α is the most upstream of the major inflammaging cytokines (it drives both IL-6 and CRP production) and is particularly responsive to weight loss and senolytic interventions. Together, the four-marker panel (hsCRP, IL-6, fibrinogen, TNF-α) provides a comprehensive view of inflammaging burden across the acute-phase, cytokine, and coagulation arms of the inflammatory response. I re-test every 6 months in active longevity patients and use trend lines, not single values, to guide intervention intensity.

Frequently Asked Questions About Inflammaging

Is inflammaging the same as having an autoimmune disease?

No — inflammaging is sterile, low-grade, and non-specific, while autoimmune disease involves directed immune attack on self-antigens with identifiable antibody profiles and tissue-specific damage patterns. However, the two interact: chronic inflammaging lowers the threshold for autoimmune flares in susceptible individuals, and autoimmune disease that persists for years contributes substantially to inflammaging burden. The practical distinction is that inflammaging is universal — everyone accumulates it with aging — while autoimmune disease requires a specific immune dysregulation event layered on top.

Do NSAIDs like ibuprofen treat inflammaging effectively?

NSAIDs suppress the prostaglandin arm of inflammation (COX-1 and COX-2 inhibition) but do not address the IL-6, TNF-α, or NF-κB drivers of inflammaging. Worse, NSAIDs inhibit COX-2-derived lipoxins, which are part of the SPM pro-resolution machinery — meaning chronic NSAID use can actually impair inflammatory resolution and worsen inflammaging over the long term. Low-dose aspirin has more complex effects: at 81 mg/day it preferentially inhibits COX-2 and triggers aspirin-triggered resolvins via a modified pathway, producing some genuine anti-inflammaging benefit, which is likely part of the mechanism behind its cardiovascular protective effects.

How does foot and ankle inflammation connect to systemic inflammaging?

In two ways. First, recurrent local inflammation in tendons, plantar fascia, and joints generates DAMP release that activates systemic NF-κB — particularly relevant in chronic tendinopathy and Charcot arthropathy. Second, the systemic inflammaging driven by metabolic dysfunction (AGEs, VAT, LPS endotoxemia) directly impairs the local healing capacity in foot and ankle tissues by suppressing the macrophage phenotype switch from inflammatory (M1) to reparative (M2) that is required for tendon and wound healing to progress. This bidirectionality is why I treat foot and ankle conditions as whole-body inflammatory events, not local mechanical problems.

What is the fastest way to reduce hsCRP?

Based on RCT evidence, the three fastest interventions are: (1) 3–4 grams per day of EPA+DHA fish oil, which produces measurable hsCRP reduction within 4 weeks; (2) 5–7% body weight loss from caloric restriction or time-restricted eating, which reduces hsCRP by 25–35% over 8–12 weeks primarily through VAT reduction; and (3) sleep normalization via CBT-I, which reduces hsCRP by ~24% over 12 weeks. Combining all three simultaneously typically produces a 40–50% reduction in hsCRP in motivated patients with moderate baseline elevation — a clinically meaningful shift from the “average” cardiovascular risk tier to the “low” tier.

Does metformin reduce inflammaging?

Yes — and this is a major part of the biological rationale for its longevity investigation beyond diabetes management. Metformin activates AMPK, which directly suppresses NF-κB activity through multiple mechanisms: AMPK phosphorylates and activates PGC-1α (improving mitochondrial biogenesis and reducing mitochondrial DAMP production), inhibits mTORC1 (reducing anabolic inflammaging drivers), and activates SIRT1 (a deacetylase that modifies NF-κB p65 and reduces its transcriptional activity). In the TAME trial (Targeting Aging with Metformin), currently underway, one of the primary biomarker endpoints is hsCRP — demonstrating that the scientific community has formally accepted inflammaging suppression as a metformin mechanism worth prospectively validating.

Bottom Line

Inflammaging is not background noise in the aging process — it is the primary signal. Every major age-related disease that kills people in developed countries has inflammaging as a required upstream event in its pathogenesis. Alzheimer’s plaque development requires neuroinflammation; atherosclerosis is an inflammatory disease of arterial walls; sarcopenia requires inflammatory inhibition of muscle protein synthesis; diabetes drives and is driven by inflammatory insulin resistance; cancer requires an inflammatory tumor microenvironment to progress.

The good news is that inflammaging is not destiny. The five-target biomarker panel — hsCRP, IL-6, fibrinogen, TNF-α, omega-3 index — provides a quantitative window into your personal inflammaging burden, and every single target responds to lifestyle and targeted nutritional interventions that are available now, without waiting for pharmaceutical development. A patient who systematically addresses their diet, sleep, exercise, VAT, and gut permeability over 12 months will have a measurably different inflammatory trajectory — and a measurably different disease risk profile — than a patient who does not.

Sources

• Franceschi C, Bonafè M, Valensin S, et al. Inflamm-aging. An Evolutionary Perspective on Immunosenescence. Ann N Y Acad Sci. 2000;908:244-254.
• Cani PD, Bibiloni R, Knauf C, et al. Changes in gut microbiota control metabolic endotoxemia-induced inflammation. Diabetes. 2008;57(6):1470-1481.
• Biagi E, Franceschi C, Rampelli S, et al. Gut microbiota and extreme longevity. Curr Biol. 2016;26(11):1480-1485.
• Xu M, Pirtskhalava T, Farr JN, et al. Senolytics improve physical function and increase lifespan in old age. Nat Med. 2018;24(8):1246-1256.
• Ridker PM, Danielson E, Fonseca FA, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein (JUPITER). N Engl J Med. 2008;359(21):2195-2207.
• Serhan CN, Chiang N, Dalli J. The resolution code of acute inflammation. Semin Immunol. 2015;27(3):200-215.
• Estruch R, Ros E, Salas-Salvadó J, et al. Primary Prevention of Cardiovascular Disease with a Mediterranean Diet (PREDIMED). N Engl J Med. 2013;368(14):1279-1290.
• Hayashino Y, Jackson JL, Hirata T, et al. Effects of exercise on C-reactive protein. Am J Epidemiol. 2014;179(4):432-440.
• Irwin MR, Olmstead R, Carroll JE. Sleep Disturbance, Sleep Duration, and Inflammation. Biol Psychiatry. 2016;80(1):40-52.

Related Articles

• Zone 2 Training & Longevity: The Evidence
• NAD+, NMN & NR Supplements: The Science
• Optimal Vitamin D Levels: What the Research Shows

Dive Deeper into Longevity

• NAD+ and Sirtuins: Longevity Pathway
• Hormesis and Longevity
• Social Connection and Longevity
• Cognitive Longevity and Alzheimer’s Prevention